How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? – Beyond the Abstract
bladder cancer, muscle-invasive bladder cancers (MIBC), PURE-01 trial, ABACUS trial, NABUCCO trial, tumor mutational burden (TMB), PI3K-AKT-mTOR signaling, tyrosine kinase receptors/RAS. Alterations, FGFR3 mutations, DNA damage response and repair (DDR) gene alterations, BRCA2 mutations, genomic profiling for bladder cancer, immunohistochemical analysis (IHC), in situ hybridization (ISH), PD-L1 expression.